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Abstract: Folate receptor (FR)-targeted radionuclide therapy using folate radioconjugates is of interest
due to the expression of the FR in a variety of tumor types. The high renal accumulation of radiofolates
presents, however, a risk of radionephropathy. A potential option to address this challenge would
be to use radioprotectants, such as amifostine. Methods for early detection of kidney damage
that—in this case—cannot be predicted based on dose estimations, would facilitate the development
of novel therapies. The aim of this study was, therefore, to assess potentially changing levels of
plasma and urine biomarkers and to determine DNA damage at an early stage after radiofolate
application. The identification of an early indicator for renal damage in mice would be useful since
histological changes become apparent only several months after treatment. Mice were injected with
different quantities of 177Lu-folate (10 MBq, 20 MBq and 30 MBq), resulting in mean absorbed kidney
doses of ~23 Gy, ~46 Gy and ~69 Gy, respectively, followed by euthanasia two weeks (>85% of the
mean renal radiation dose absorbed) or three months later. Whereas all investigated biomarkers
remained unchanged, the number of γ-H2AX-positive nuclei in the renal cortex showed an evident
dose-dependent increase as compared to control values two weeks after treatment. Comparison
with the extent of kidney injury determined by histological changes five to eight months after
administration of the same 177Lu-folate activities suggested that the quantitative assessment of
double-strand breaks can be used as a biological indicator for long-term radiation effects in the
kidneys. This method may, thus, enable faster assessment of radiopharmaceuticals and protective
measures by preventing logistically challenging long-term investigations to detect kidney damage.
Keywords: radiation nephropathy; kidney; 177Lu; radiofolate; γ-H2AX; DNA double-strand breaks
1. Introduction
The concept of targeted radionuclide therapy takes an advantage of the expression of a
tumor-associated receptor or antigen and a ligand for targeting that can be labeled with a
therapeutic radionuclide. Radionuclide therapy using peptide-based and other small molecular-weight
radioligands is already established in the clinics, however, only for a limited number of tumor types [1].
One of the challenges during the development of novel radionuclide therapies is the undesired
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accumulation of radioactivity in healthy organs and tissues. Among the organs at risk are the kidneys
due to renal excretion of small molecular-weight radiopharmaceuticals [2].
The toxic effects of radiation to the kidneys are associated with a plethora of morphological and
functional changes which are referred to as radiation nephropathy [3,4]. This is a chronic, progressive,
irreversible condition that occurs in both humans and laboratory animals and is characterized by
a late, but sudden onset of glomerular and tubular alterations eventually leading to end-stage
kidneys [4]. Radiation nephropathy is associated with injury to all renal compartments, such as
the glomeruli (glomerulosclerosis and mesangial proliferation), the tubulo-interstitial compartment
(tubular atrophy and interstitial fibrosis) and the renal vasculature (occlusive thrombotic and
non-thrombotic lesions) [4,5].
Over the years, different strategies were reported to overcome the problem of radiation-induced
kidney toxicity, including application of diuretic agents to increase renal excretion of the compound
or positively charged amino acids to decrease the accumulation of the radioactivity in kidneys [6,7].
An alternative option to reduce the risk of radionephropathy could be the application of radioprotective
agents such as amifostine. It is applied as a prodrug and converted into an active radical scavenger
by an alkaline phosphatase present in renal tissue [8]. The radioprotective mechanism of amifostine
was also reported to be associated with rapid oxygen consumption, resulting in cellular anoxia,
and thus, reduced effects of radiation [8]. Rolleman et al. have shown that the treatment of rats with
radiolabeled somatostatin analogs in combination with amifostine significantly decreased kidney
damage in comparison with radionuclide therapy alone [9]. Amifostine-treated animals showed
absence of body weight loss, lower histopathological scores of kidney damage and higher uptake
of 99mTc-DMSA in the kidney indicative of intact renal function [9]. Amifostine (EthyolTM) is the
only radioprotectant approved for clinical use so far; however, investigations of other radioprotective
agents, including blockers of oxygen consumption, free-radical scavengers, DNA repair boosters and
others are ongoing [10].
The folate receptor alpha (FR) is expressed in many tumor types of epithelial origin,
most prominently in ovarian, endometrial and lung cancer [11,12]. The development of FR-targeted
radionuclide therapy using folic acid conjugates of therapeutic nuclides would, therefore, be of high
interest. The potential of this therapy concept has been demonstrated in preclinical settings [13];
however, translation to the clinics was not feasible so far, due to the high renal accumulation of
radiofolates, which poses the risk of damage to the kidneys. Several attempts to reduce the kidney
uptake of radiofolates were made in past years, among those also the use of agents which may
modulate the tissue distribution [14]. The concept of using kidney-selective radioprotective agents has
not been investigated so far in combination with radiofolates even though it seems promising.
Histological features consistent with radiation nephropathy in laboratory animals are observed
only months after external beam radiation or radionuclide therapy, while the early stages after radiation
exposure are dominated by subtle histological changes that vary between different species [4,15].
In general, the majority of markers of radiation-induced kidney damage are visible only weeks or even
months after start of the therapy [4]. Assessment of murine radiation nephropathy requires, therefore,
long-term in vivo experiments, which are logistically challenging.
It is commonly accepted that an absorbed kidney dose of 23 Gy is the safe upper limit [16].
The physically calculated dose does, however, not take the action of radioprotective agents into
account, hence, the dose calculation in such case is not a reliable measure to predict long-term effects
after radionuclide therapy. The establishment of methods that allow determination of radiation effects
in the renal tissue predictive for long-term damage would enable more rapid development of protective
measures such as the use of antioxidants.
In this study, renal tissue sections of mice that were euthanized two weeks or three
months after injection of different activities of 177Lu-folate were investigated histologically and an
immunohistochemical analysis of phosphorylated histone H2AX (γ-H2AX), a double-strand break
(DSB) marker [17], was performed. Quantification of γ-H2AX may possibly allow determination of
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the degree of kidney irradiation which would cause long-term renal damage and serve as a valid
marker for the protective effect of radical scavengers and other radioprotective agents. In this study,
we also analyzed urine and plasma samples of the same mice. These included the determination of
commonly used endogenous markers of renal function, such as plasma levels of blood urea nitrogen
and creatinine, as well as urinary biomarkers considered to indicate acute tubular injury.
2. Results and Discussion
One of the main advantages of radionuclide therapy is the possibility to deliver a radioactive
source to the malignant tissue by targeting a tumor-specific receptor or antigen [1]. Organs other
than the target tissues, however, may be exposed to radiation as well, as occurs in the kidneys due to
renal excretion of the radioconjugates [7,18–20]. Accordingly, undesired side effects of radionuclide
therapy often include chronic, slowly progressing loss of kidney function [2]. This is particularly
true in the case of folate-based radioconjugates as they bind specifically to the FR, expressed in the
renal proximal tubules [21]. The development of an early marker that could be predictive of late
renal radiation-induced injury would be of major benefit for the assessment of radiopharmaceutical
candidates in preclinical studies. In the present study, we investigated DSBs as short-term indicators
of radiation effects which may serve as a measure for kidney damage when dose calculations cannot
be applied. In addition, we determined the morphological changes in the renal tissue (Table 1)
and assessed urine and blood plasma parameters, elevated in acute kidney injury (Supplementary
Materials, Table S1), of mice two weeks and three months after application of 177Lu-folate.
2.1. Effect of 177Lu-Folate Treatment on Body Weights of Mice
Groups of six mice received either only saline or 177Lu-folate at different activities (10 MBq,
20 MBq and 30 MBq), corresponding to mean absorbed kidney doses of 23 Gy, 46 Gy and 69 Gy,
respectively (Table 2) [22]. The body weight and general health status of mice were monitored over the
whole study period. Directly before treatment of the mice, the average body weights (19.8–20.4 g) did
not differ significantly between the various groups of mice. The weight gain over the first two weeks
was similar in all groups (0.7–17%) resulting in RBWs of 1.17 ± 0.06, 1.13 ± 0.06 and 1.07 ± 0.06 in
mice that received 10 MBq, 20 MBq and 30 MBq 177Lu-folate, respectively, and 1.13 ± 0.06 in untreated
control mice. After three months, the RBW of mice increased to 1.15–1.30 (Figure 1). These results
indicated that 177Lu-folate did not have any effect on the body weight of the mice in the first three
months, which is in accordance with long-term studies, where the body weight of control mice and
treated mice remained stable over the whole study period of eight months [15]. Only the mice treated
with high activity of 177Lu-folate (30 MBq) were found to progressively lose body weight from week
15 onwards and reached endpoint criteria which required euthanasia between week 15 and 26 post
treatment [15].
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Figure 1. Relative body weights of animals treated with different activities of 177Lu-folate (10 MBq,
20 MBq or 30 MBq). Data points represent an average of six mice per group up to two weeks and of
three mice per group from Week 2 until Week 13 post treatment.
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2.2. Effect of 177Lu-Folate Treatment on the Levels of Urine and Plasma Biomarkers
Urinary markers, such as kidney injury molecule-1 (Kim-1), neutrophil gelatinase-associated
lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG) and interleukin-18 (IL-18) have been
previously reported to rise as a result of acute tubular injury [23,24]. In our study, the levels of
these biomarkers remained, however, unchanged in all groups of mice independent of the applied
dose. Cystatin C was the only parameter that increased slightly in treated mice that received high
activity of 177Lu-folate (30 MBq) as compared to control mice and mice which received lower activities
(131–145 ng/mg CRE) (Supplementary Materials, Table S1). The urinary levels of cystatin C were
reported to rise after tubular injury [25–27]. Increased levels of cystatin C, in the absence of changes
of other markers of acute kidney injury, have been previously described also in rats, where a 3-fold
increase in cystatin C compared to the control was detected 24 h after exposure to total body irradiation
with x-rays [28]. However, in our study, the cystatin C levels did not change significantly and,
even though the cohort of mice was very small, it is unlikely that cystatin C could be used as a
biological indicator for the prediction of long-term radionephropathy.
Investigation of plasma samples from mice euthanized two weeks after injection of 177Lu-folate
also did not show significant changes in blood urea nitrogen (BUN), creatinine (CRE) and Kim-1
levels. These results indicate that the plasma biomarkers used in this study cannot be employed for
prognostication of radiation-induced long-term renal damage.
2.3. Renal Weight and Histopathological Observations
In a previous study, in which the long-term damage of kidneys was investigated, a significant
reduction in renal size was reported at five to eight months after treatment with 177Lu-folate [22].
A kidney dose of 23 Gy resulted in an absolute kidney weight reduction of 23% as compared to control
mice after eight months. Higher mean absorbed kidney doses (46 Gy and 69 Gy) resulted in renal
weight decreases of 32% and 61%, respectively (unpublished data). These findings are in agreement
with those of clinical studies, where a progressive decrease in kidney size was observed over a period
of eight years in patients that had undergone abdominal radiation therapy [29].
In mice euthanized two weeks after administration of 20 MBq and 30 MBq 177Lu-folate, a slight,
but not significant reduction of kidney weight was noted as compared to the kidney weight of
control mice and mice injected with 10 MBq 177Lu-folate. In mice that were euthanized after three
months, there was no weight difference in the kidneys, compared to those of the concurrent controls.
This indicates that renal weights at these early time points are not indicative of long-term renal injury.
At two weeks after application of 177Lu-folate, kidneys did not exhibit any histological changes
(Table 1, Supplementary Materials, Figure S1). This was also true for the kidneys of mice euthanized
three months after application of 177Lu-folate at an activity of 10 MBq, resulting in a mean absorbed
kidney dose of 23 Gy (final score 0, determined according to the scoring system shown in Table 3).
In mice which received 20 MBq 177Lu-folate, resulting in a mean absorbed kidney dose of 48 Gy, slight
renal damage consisting of scattered groups of degenerated tubules was observed in one of three mice,
resulting in a final score of 1. However, no damage was observed in the two other mice receiving
the same activity of 177Lu-folate (final score 0) (Figure 2, Table 1). Mild nephropathy with a final
score of 2 was detected in mice that had received high activity of 177Lu-folate (30 MBq) resulting in
a mean absorbed kidney dose of 69 Gy (Figure 2, Table 1). This was characterized by deposition of
proteinaceous material and a reduced number of capillaries in the glomeruli, as well as multifocal
cortical tubular degeneration and collapse. These results are in line with those of the previously
performed long-term study [15], where mice that received high activities of 177Lu-folate (30 MBq) had
to be euthanized five or six months after treatment due to progressive body weight loss and signs of
unease. Morbidity was attributed to radiation nephropathy with an average score 4 (Table 1).
The histological data indicate that the earliest evidence of radiation-induced renal injury after
injection of 177Lu-folate can be observed after three months, as low grade (minimal or mild) renal
damage in the high-dose group and, to a minimal extent, the mid-dose group. These findings are
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in agreement with the onset of a dose-dependent renal damage around this time after 177Lu-folate
treatment, which obviously progresses with time, leading to the degree of damage seen at later
stages [15].
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Figure 2. Histological findings in the renal cortex of ice euthanized three months after injection of
(A) saline, (B) 10 MBq 177Lu-folate, (C) 20 MBq 177 -f l te and (D) 30 MBq 177Lu-folate. (A/B) No
histological changes were observed in the cont lo -dose group. (C) In the mid-dose group,
changes w re r stricted o the presence of scatter d groups of degenerate l (arrow) in one of the
three examined animals (final score 1). (D) In the high-dose group, mild kidney injury was observed
(3/3 mice, final score 2) represented by multifocal tubular degeneration (arrows) and slight enlargement
of glomeruli with fewer capillaries (arrowheads). Higher magnification of representative glomeruli
(black squares) and tubular lesions (red squares) indicated by arrows (insets are 5× magnified as
compared to the images).
Table 1. Histological evaluation of 177Lu-folate induced renal changes in mice.
177Lu-folate
(MBq)
Time of
Euthanasia
Score Glomeruli
(Average)
Score Tubules
(Av rage)
Score Interstitium
(Average)
Cumulative
Score Final Score *
Results of the present study
-
2 weeks
0 0 0 0 0
10 0 0 0 0 0
20 0 0 0 0 0
30 0 0 0 0 0
-
3 months
0 0 0 0 0
10 0 0 0 0 0
20 0 0.3 0 0.3 0 (n = 2);1 (n = 1)
30 2.0 1.5 0 3.5 2
Results of a previous study reported by Haller et al. [15]
-
8 months
0 0 0 0 0
10 2.0 1.5 0.4 3.9 2
20 3.8 3.3 3.3 10.4 3
30 5–6 months ** 5 4.2 4.6 13.8 4
* In the HE-stained sections, each renal compartment was evaluated separately and given a partial score ranging
from 0 to 5. Partial scores were then summed (=cumulative score) and converted to a final score, indicating the
degree of renal injury according to Table 3 [15]. ** Mice reached an endpoint criterion (body weight loss) between 5
and 6 months after 177Lu-folate application.
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2.4. Immunohistological Detection of DNA Double-Strand Breaks
DNA damage is the first manifestation of radiation effects in tissue [30]. Among the proteins
involved in the early steps of the cellular response to DNA damage is γ-H2AX, the phosphorylated
form of the histone protein H2AX. Over many years γ-H2AX has been used as a marker to monitor
the formation and persistence of DNA DSBs and the reparative response to DNA damage for the
evaluation of the efficacy of cancer therapies, as well as a tool to address radiobiological questions
and investigations using biodosimetry [17,31–34]. It has previously been reported that γ-H2AX is
detectable very early after in vitro exposure of cells to ionizing radiation, reaching maximum levels
within 15–30 min after irradiation, followed by a decline over several hours due to rejoining of the
DSBs [35]. A decline of γ-H2AX positive cells in tissues, including the kidneys of mice irradiated with
x-rays, has been reported to occur within ~23 h [36]. Nevertheless, γ-H2AX levels were analyzed in
this study after absorption of >85% of the radiation dose which, according to the biodistribution data
previously obtained with the 177Lu-folate, is reached about 14 days after radiofolate injection [22].
We determined a significant increase in the proportion of γ-H2AX-positive nuclei in the renal
cortex of all treated groups as compared to the low basal level seen in the untreated controls two weeks
after injection of 177Lu-folate (Figures 3A–D and 4A). The presence of γ-H2AX was generally rare
in cells within the glomerulus. An exception were the kidneys of mice that received high activities
of 177Lu-folate (30 MBq), in which the positive nuclei count limited to the glomerular area revealed
a prominent, statistically significant increase of γ-H2AX (Figure 3).
In the renal cortices of mice euthanized two weeks after injection of 10 MBq, 20 MBq and 30 MBq
177Lu-folate, ~2.7, ~4.1 and ~7.5 (~1.5%, ~2.5% and ~4.1% of the total nuclei) γ-H2AX-positive nuclei
per high-power field were counted, respectively (Figure 4). In contrast, the kidneys of untreated mice
exhibited very low levels of γ-H2AX-positive nuclei (~0.1 nuclei per high-power field corresponding
to ~0.2% of total nuclei). The increase in the number and proportion of γ-H2AX-positive nuclei was
significant and clearly dose-related. These findings were in agreement with dose-dependent radiation
effects in tissue caused by external radiation therapy [37]. Importantly, dose-dependent increase in the
number of DSBs was seen in the absence of microscopic changes in the kidneys, that is, long before
morphological evidence of radiation nephropathy (Supplementary Materials, Figure S1).
A clearly less obvious result was obtained in mice euthanized three months after injection of
177Lu-folate (Figure 3E–H), as the amount of DSBs in kidney tissues of treated mice was comparable to
the basal level.
The strong, dose-dependent γ-H2AX formation in the kidneys two weeks after radiofolate
injection indicated that γ-H2AX represents a potentially useful marker for the early evaluation of
radiation nephropathy. The time point for determination of DSB cannot be seen as a best after two
weeks, but would critically depend on the tissue distribution of a particular radioligand and the
residence time in the kidneys.
Glomeruli of mice exposed to low activities of 177Lu-folate showed negligible nuclear γ-H2AX
staining similar to control mice. The highest activity of 177Lu-folate (30 MBq, resulting in a mean
absorbed kidney dose of 69 Gy) was, however, associated with a sharp, statistically significant increase
in the formation of γ-H2AX foci in glomerular cells at the two-week time point. In a previous
long-term study [15], severe widespread glomerulosclerosis was observed in mice that had received
the same activity, euthanized five to six months after 177Lu-folate application, resulting in an average
partial glomerular score of 5 [15]. This was more severe than the kidney damage in mice euthanized
eight months after treatment with 10 MBq and 20 MBq 177Lu-folate, where the average histological
glomerular injury score was 2.0 and 3.8, respectively.
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increased in a dose-related manner in mice at two weeks (B–D), and to a lesser extent and only in
t e mid- and high-dose groups in ice at three months (G,H). γ-H2AX-positive nuclei in tubular
epith lial cells, glomeruli and interstitium are indicated with ar ows, open arrowheads and solid
arrowheads, respectively.
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2.5. Correlation of Biological Markers with a Long-Term Kidney Damage
It is known from the literature, that protective agents may influence the effect of radiation on the
tissue. As a result, the calculated dose of applied activity may not be an accurate measure to predict
the toxicity of such therapy, thus, biological markers would be of high relevance [9]. The functional
and morphological aspects of chronic nephrotoxicity, induced by the treatment with 177Lu-folate
in mice, were assessed in a previous study [15,22] and used herein to assess the value of short-
and mid-term biological indicators of radiation effects as investigated in the present study. In the
studies by Haller et al. [15,22], nude mice were monitored over a period of five to eight months
after the application of various activities of 177Lu-folate (10 MBq, 20 MBq and 30 MBq per mouse).
Striking dose-dependent nephrotoxicity was indicated by decreased renal uptake of 99mTc-DMSA over
time, increased levels of BUN and CRE as well as marked cortical scarring and glomerulosclerosis
determined in the kidneys of mice after euthanasia. The quantification of γ-H2AX, investigated two
weeks after injection of 177Lu-folate, correlated strongly with the long-term kidney damage (r2 = 0.95),
represented by the final histological score previously determined by Haller et al. (Figure 5) [15].
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In the context of the present study, caution is warranted when trying to identify cutoff levels
of γ-H2AX formation predictive for long-term radionephropathy as th s mple size was m ch too
small to yield quantitatively reli ble results. However, in terms of directions f r future res arch, it will
b important to identify robust threshold levels of γ-H2AX, as a biological indicator of radiation
effects independent of the calculated dose, f r a rapid ev luati n of kidney toxicity in studies where
ra ionuclide ther py will be combined with radioprotectants.
3. Conclusions
Increa ed numbers of γ-H2AX nuclei, determined two weeks aft r application of 177Lu-f lat
when >85% of t mean radiation dose to the kidneys was absorbed, correlated well with the severity
of long-term renal damage.
Our results suggest that quantification of nuclear phosphorylated H2AX as a biological indicator
for radiation effects independent of the calculated absorbed dose may be useful to predict long-term
renal damage and could facilitate the development of methods using radioprotectants in combination
with targeted radionuclide therapies. The proposed concept is likely translatable from radiofolates
to the application of other radiopharmaceuticals where kidneys are at risk to be damaged. Further
and more detailed preclinical studies are warranted to corroborate this outcome and investigate the
concept in more detail.
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4. Materials and Methods
4.1. Preparation of 177Lu-folate
The DOTA-folate conjugate containing an albumin-binding entity (cm09, herein referred to as
“folate” [21]) was previously developed in our group. No-carrier added 177LuCl3 was kindly provided
by Isotope Technologies Garching (ITG GmbH, Garching, Germany). Radiolabeling of the folate
conjugate was performed in a mixture of HCl (0.05 M) and Na-acetate (0.5 M) at pH 4.5 and elevated
temperature (10 min at 95 ◦C). Quality control of 177Lu-folate was carried out using high-performance
liquid chromatography (HPLC) as previously reported [21]. The radiolabeling of the folate compound
at the specific activity of up to 20 MBq/nmol was achieved with a radiochemical purity of >97%.
4.2. Animal Experiments
Animal experiments were approved by the local veterinary authorities and conducted in
accordance with the Swiss legislation for animal experiments. Female athymic nude mice
(Crl:CD1-Foxn1nu, 5–7-week-old) were purchased from Charles River Laboratories (Sulzfeld,
Germany). Animals were fed with a folate-deficient rodent diet (ssniff Spezialdiäten GmbH, Soest,
Germany), starting one week prior to the injection of the radiofolate. Mice were divided into four
groups of six animals each and were intravenously (i.v.) injected with saline or 177Lu-folate at
therapeutic quantities of activity (10 MBq, 20 MBq and 30 MBq, respectively). The determination of
the mean absorbed dose to the kidneys has been reported previously (Table 2) [22].
Table 2. Mean absorbed kidney doses in nude mice after the injection of different quantities of
177Lu-folate calculated in previous studies [22].
Saline 177Lu-folate
Injected activity (MBq) - 10 20 30
Kidney dose (Gy) - ~23 ~46 ~69
End-point criteria were defined as weight loss of >15% of the initial body weight and/or signs
indicating pain and unease. Body weights were measured twice a week for the determination of the
relative body weight (RBW = WX/W0; with WX = body weight at day x and W0 = body weight at
day 0) and indicated as average RBW for each group. Animals of each group (n = 6) were euthanized
two weeks (n = 3) or three months (91 days, n = 3) after injection of the 177Lu-folate, respectively.
The long-term effects to the kidneys after treatment of mice with 177Lu-folate were previously evaluated
over a period of 5–8 months and reported by Haller et al. [15,22]. Data from these experiments were
used in the present study for comparative purposes.
4.3. Determination of Plasma and Urinary Markers
Analysis of plasma and urinary markers is described in Supplementary Materials. Investigated
markers included creatinine and blood urea nitrogen, kidney injury molecule-1 (KIM-1, designed as
Kim-1 in rodents), neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase
(NAG), cystatin C and interleukin-18 (IL-18) [38].
4.4. Necropsy, Tissue Processing and Histological Examination
All animals were euthanized by exsanguination after CO2 asphyxiation. After dissection
of the animals and a full macroscopic examination, the kidneys were weighed and fixed in 4%
neutral-buffered formalin (Formafix, Hittnau, Switzerland). Kidneys were trimmed (longitudinal
and cross-sections of both kidneys), dehydrated through graded alcohols and routinely paraffin wax
embedded. Consecutive sections (3–5 µm) were prepared, mounted on glass slides and routinely
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stained with hematoxylin eosin (HE) or subjected to immunohistochemical staining. Renal injury was
assessed and scored in HE-stained sections, as previously reported (Table 3) [15].
Table 3. Scoring scheme for the assessment of renal injury [15]. A cumulative score, obtained by the
addition of scores for the changes in each compartment (glomeruli, tubules and interstitium) was
converted to a final score as an indicator of the overall degree of renal injury.
Cumulative Score
(Glomeruli, Tubules, Interstitium) Final Score Renal Injury
0–0.9 0 no histological abnormality
1.0–2.9 1 minimal
3.0–6.9 2 mild
7.0–10.9 3 moderate
11.0–13.9 4 marked
14.0–15.0 5 severe
4.5. Immunohistochemistry for the Detection of DNA Double-Strand Breaks
The immunohistochemical staining for the phosphorylated γ-H2AX histone antigen served for
the determination of DNA double-strand breaks (DSBs) [39]. Briefly, sections were deparaffinized
in xylene and rehydrated through graded ethanol. For antigen retrieval, sections were incubated in
10 mM Tris-EDTA buffer (pH 9.0) for 15 min at 98 ◦C. This was followed by incubation with rabbit
anti-mouse γ-H2AX antibody (polyclonal antibody #2577, Cell Signaling Technology, Danvers, MA,
USA, 1:50 dilution in Dako antibody diluent, Dako-Agilent Technologies, Denmark) overnight at
4 ◦C. Afterwards, the slides were incubated for 30 min with a horseradish peroxidase (HRP)-labeled
polymer, conjugated to a secondary anti-rabbit antibody (Dako EnvisionTM System, Dako-Agilent
Technologies). The reaction was visualized using 3,3’-diaminobenzidine (DAB) as chromogen,
followed by light counterstain with hematoxylin. The immunohistochemical staining was performed
using an Autostainer (Dako Autostainer Universal Staining System Model LV-1, Dako-Agilent
Technologies). A formalin-fixed, paraffin-embedded human tumor xenograft obtained after irradiation
of a tumor-bearing mouse served as positive control, and kidney sections incubated with the dilution
buffer without primary antibody served as negative controls.
All labeled slides were scanned using a digital slide scanner (NanoZoomer-XR C12000;
Hamamatsu, Japan), and the number of nuclei exhibiting staining for γ-H2AX was calculated in the
digital slides using the Visiopharm Integrator System (VIS, version 4.5.1.324, Visiopharm, Hørsholm,
Denmark). Briefly, 30 regions of interest (ROIs) with a size of 0.237 mm2 (the area of a high-power
field with one ocular of 22 mm field of view), were randomly selected across the renal cortex of all
animals. A threshold classification allowed recognition of positive (brown) and negative nuclei in
each ROI, and the results were expressed as % of positive nuclei per ROI. To selectively measure
the amount of positive nuclei in the glomeruli, the same analysis was carried out on ROIs that were
created by manual drawing over 30 consecutive glomeruli per kidney. The quantitative analysis was
performed by two independent investigators and expressed as the average of the two sets of data. The
automated system was validated based on the numbers obtained in the same ROI by manual counting
by an investigator.
4.6. Statistical Analysis
Data are presented as mean ± standard. Statistical analyses were conducted using one-way
ANOVA with Bonferroni’s multiple comparison post-test (GraphPad Prism, version 5.01).
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Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/10/2/57/s1,
Table S1: Urine biomarkers of acute renal injury in 177Lu-folate treated mice, Figure S1: Histological findings in
HE-stained kidney tissue sections of mice euthanized two weeks after injection of saline, 10 MBq 177Lu-folate,
20 MBq 177Lu-folate and 30 MBq 177Lu-folate.
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